Breaking News Instant updates and real-time market news.

ACRS

Aclaris Therapeutics

$6.23

0.35 (5.95%)

07:11
04/24/19
04/24
07:11
04/24/19
07:11

Aclaris Therapeutics announces issuance of patent for the use of ruxolitinib

Aclaris Therapeutics announced that the United States Patent and Trademark Office, or USPTO, issued U.S. Patent No. 10,265,258 covering methods of treating alopecia areata, or AA, using ruxolitinib or isotopic forms of ruxolitinib. This newly issued patent is the latest in a series of patents granted by the USPTO which are exclusively licensed to Aclaris by The Trustees of Columbia University in the City of New York in connection with Aclaris' janus kinase, or JAK, inhibitor program for hair loss disorders. This IP arose out of the research conducted by Angela Christiano and her team at Columbia University. The claims in this issued patent cover the use of an effective amount of isotopic forms of ruxolitinib, including deuterated ruxolitinib, to treat AA.

  • 06

    May

  • 05

    Jun

ACRS Aclaris Therapeutics
$6.23

0.35 (5.95%)

10/16/18
JMPS
10/16/18
NO CHANGE
Target $34
JMPS
Outperform
Aclaris Therapeutics price target lowered to $34 from $47 at JMP Securities
JMP Securities analyst Donald Ellis lowered his price target on Aclaris Therapeutics (ACRS) shares to $34 from $47 after the company announced a deal to acquire Rhofade from Allergan (AGN) and disclosed unaudited Q3 Eskata sales of about $0.5M, which missed his prior estimate of $2.8M. His lower price target is attributable to his updated Eskata estimates with the launch proceeding slower than expected, but Ellis maintains an Outperform rating on Aclaris shares, stating that he sees the Rhofade deal as "strategic and accretive."
12/18/18
MZHO
12/18/18
NO CHANGE
Target $26
MZHO
Buy
Concert remains best-in-class after Aclaris data, says Mizuho
Mizuho analyst Difei Yang reiterates a Buy rating on Concert Pharmaceuticals (CNCE) after competitor Aclaris Therapeutics (ACRS) reported data from its topical Janus kinase 1/3 inhibitor for the treatment of alopecia areata. While a number of patients were responders in the eyebrow and alopecia totalis/alopecia universalis Phase 2 trials, improvements on Severity of Alopecia Tool scores were not disclosed and a few patients withdrew from the studies, Yang tells investors in a research note. The analyst sees Concert Pharmaceuticals' CTP-543 as best-in-class and more competitive for the treatment of moderate/severe alopecia areata. Yang keeps a $26 price target on Concert shares.
12/18/18
CANT
12/18/18
NO CHANGE
Target $50
CANT
Overweight
Aclaris data positive despite patient withdrawals, says Cantor Fitzgerald
Aclaris Therapeutics' data for ATI-502 were positive, despite patient withdrawals by participants that were typically lost to follow-up or who withdrew due to lack of effect, Cantor Fitzgerald analyst Louise Chen tells investors in a research note titled "Don't Need a Gingerbread Man to Make Your Life Sweet; Catch ACRS's Stock Instead." She believes the positive updates underscore that Aclaris' drugs "can treat tough patient populations and provide a positive read-through to additional readouts coming in 2019." The data also demonstrate that a topical JAK can work, contends the analyst. Chen keeps an Overweight rating on Aclaris Therapeutics with a $50 price target.
12/31/18
CANT
12/31/18
NO CHANGE
Target $50
CANT
Overweight
Aclaris market cap should be much greater than $300M, says Cantor Fitzgerald
With two commercial drugs, Rhofade and Eskata, and up to six positive data readouts in 2019, Aclaris Therapeutics' market capitalization should be much greater than $300M, Cantor Fitzgerald analyst Louise Chen tells investors in a research note titled "Don't Make Me Tell You Until I'm Red In The Face." The analyst believes Rhofade's soft re-launch, which started on November 1, is gaining traction and that the drug's "positive momentum is not getting the attention that it deserves." Chen previously highlighted Aclaris as one of her top ideas heading into 2019 and she keeps an Overweight rating on the shares with a $50 price target.

TODAY'S FREE FLY STORIES

FDX

FedEx

$156.00

-4.88 (-3.03%)

17:46
06/25/19
06/25
17:46
06/25/19
17:46
Hot Stocks
FedEx says international commercial team still poised for growth »

Says TNT Express…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Jun

  • 30

    Jul

  • 31

    Jul

  • 13

    Nov

FDX

FedEx

$156.00

-4.88 (-3.03%)

17:43
06/25/19
06/25
17:43
06/25/19
17:43
Hot Stocks
FedEx says global trade picture 'less than ideal' »

Says "all-in"…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Jun

  • 30

    Jul

  • 31

    Jul

  • 13

    Nov

FDX

FedEx

$156.00

-4.88 (-3.03%)

17:38
06/25/19
06/25
17:38
06/25/19
17:38
Hot Stocks
FedEx calls FY20 a 'transition year' »

Says FY20 a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Jun

  • 30

    Jul

  • 31

    Jul

  • 13

    Nov

FDX

FedEx

$156.00

-4.88 (-3.03%)

17:37
06/25/19
06/25
17:37
06/25/19
17:37
Hot Stocks
FedEx says intends to substantially grow e-commerce business »

Sees FedEx Freight will…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Jun

  • 30

    Jul

  • 31

    Jul

  • 13

    Nov

CNX

CNX Resources

$6.83

-0.345 (-4.81%)

17:36
06/25/19
06/25
17:36
06/25/19
17:36
Hot Stocks
CNX Resources director Bernard Lanigan purchases 36,200 shares of company stock »

CNX Resources director…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

FTI

TechnipFMC

$24.96

0.21 (0.85%)

17:32
06/25/19
06/25
17:32
06/25/19
17:32
Hot Stocks
TechnipFMC confirms settlement with U.S., Brazilian enforcement authorities »

TechnipFMC has agreed to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Jul

  • 27

    Aug

MO

Altria Group

$48.80

0.31 (0.64%)

, BTI

British American Tobacco

$35.76

0.56 (1.59%)

17:25
06/25/19
06/25
17:25
06/25/19
17:25
Periodicals
San Francisco votes to ban sale of e-cigarettes, AP reports »

San Francisco, California…

MO

Altria Group

$48.80

0.31 (0.64%)

BTI

British American Tobacco

$35.76

0.56 (1.59%)

PM

Philip Morris

$78.85

1.02 (1.31%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CVS

CVS Health

$53.69

0.57 (1.07%)

17:16
06/25/19
06/25
17:16
06/25/19
17:16
Recommendations
CVS Health analyst commentary at Tigress Financial »

Tigress Financial sees…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

FTI

TechnipFMC

$24.96

0.21 (0.85%)

17:15
06/25/19
06/25
17:15
06/25/19
17:15
Hot Stocks
TechnipFMC, subsidiary to pay $296M to resolve foreign bribery charges »

TechnipFMC and its…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Jul

  • 27

    Aug

ORRF

Orrstown Financial

$21.93

0.22 (1.01%)

17:11
06/25/19
06/25
17:11
06/25/19
17:11
Hot Stocks
Orrstown Financial names Thomas Brugger EVP and CFO »

Orrstown Financial…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MU

Micron

$32.71

-0.47 (-1.42%)

17:07
06/25/19
06/25
17:07
06/25/19
17:07
Hot Stocks
Micron says it has mitigated 90% of China tariff impact »

Says U.S. tariffs on…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Jun

  • 09

    Jul

AGN

Allergan

$162.60

32.95 (25.41%)

, ABBV

AbbVie

$65.63

-12.78 (-16.30%)

17:07
06/25/19
06/25
17:07
06/25/19
17:07
On The Fly
Fly Intel: Wall Street's top stories for Tuesday »

Stocks muddled through a…

AGN

Allergan

$162.60

32.95 (25.41%)

ABBV

AbbVie

$65.63

-12.78 (-16.30%)

TMUS

T-Mobile

$74.56

-0.98 (-1.30%)

S

Sprint

$6.82

-0.04 (-0.58%)

DISH

Dish

$37.80

-0.79 (-2.05%)

LEN

Lennar

$48.24

-3.17 (-6.17%)

FDX

FedEx

$156.00

-4.88 (-3.03%)

UPS

UPS

$97.11

-2.58 (-2.59%)

FB

Facebook

$188.87

-3.69 (-1.92%)

PYX

Pyxus

$17.06

3.635 (27.09%)

GRUB

GrubHub

$76.01

3.96 (5.50%)

ALDX

Aldeyra

$6.21

-0.87 (-12.29%)

W

Wayfair

$144.54

-7.925 (-5.20%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Jun

  • 25

    Jun

  • 25

    Jun

  • 25

    Jun

  • 25

    Jun

  • 26

    Jun

  • 27

    Jun

  • 27

    Jun

  • 28

    Jun

  • 09

    Jul

  • 10

    Jul

  • 16

    Jul

  • 24

    Jul

  • 30

    Jul

  • 31

    Jul

  • 16

    Sep

  • 13

    Nov

AITB

AIT Therapeutics

$5.33

0.06 (1.14%)

17:05
06/25/19
06/25
17:05
06/25/19
17:05
Hot Stocks
AIT Therapeutics plans to file PMA submission with FDA for PPHN with AirNOvent »

On track to file a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MU

Micron

$32.71

-0.47 (-1.42%)

17:03
06/25/19
06/25
17:03
06/25/19
17:03
Earnings
Micron sees Q4 EPS 45c +/- 7c, consensus 78c »

Sees Q4 revenue $4.5B +/-…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Jun

  • 09

    Jul

AITB

AIT Therapeutics

$5.33

0.06 (1.14%)

17:00
06/25/19
06/25
17:00
06/25/19
17:00
Earnings
AIT Therapeutics reports Q4 EPS (49c), consensus 28c »

Reports Q4 revenue $7.7M,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MU

Micron

$32.71

-0.47 (-1.42%)

16:48
06/25/19
06/25
16:48
06/25/19
16:48
Hot Stocks
Micron says it can resume shipping a certain subset of products to Huawei »

Says expects healthy…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Jun

  • 09

    Jul

AVAV

AeroVironment

$61.41

-0.52 (-0.84%)

16:42
06/25/19
06/25
16:42
06/25/19
16:42
Hot Stocks
AeroVironment down 9.5% to $55.50 after Q4 results, FY20 guidance »

The midpoint of the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Jun

BBVA

Banco Bilbao

$5.52

-0.05 (-0.90%)

16:40
06/25/19
06/25
16:40
06/25/19
16:40
Syndicate
Breaking Syndicate news story on Banco Bilbao »

Banco Bilbao files…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Oct

CRTO

Criteo

$18.00

-0.05 (-0.28%)

16:39
06/25/19
06/25
16:39
06/25/19
16:39
Hot Stocks
Criteo COO Mollie Spilman to leave company »

Criteo S.A. announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

KHC

Kraft Heinz

$30.68

0.17 (0.56%)

16:37
06/25/19
06/25
16:37
06/25/19
16:37
Hot Stocks
Kraft Heinz accelerates new CEO start date to June 25 »

In a regulatory filing,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SPOT

Spotify

$144.12

-5.99 (-3.99%)

16:34
06/25/19
06/25
16:34
06/25/19
16:34
Periodicals
Spotify chief revenue officer Brian Benedik to depart, The Information reports »

Spotify's chief…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

16:34
06/25/19
06/25
16:34
06/25/19
16:34
General news
API crude inventories for week of June 21 »

API reports that crude…

GBCI

Glacier Bancorp

$39.23

-0.06 (-0.15%)

16:34
06/25/19
06/25
16:34
06/25/19
16:34
Hot Stocks
Glacier Bancorp raises dividend to 27c from 26c »

Glacier Bancorp declared…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Aug

NSRGY

Nestle

$0.00

(0.00%)

, NVS

Novartis

$92.37

-0.41 (-0.44%)

16:33
06/25/19
06/25
16:33
06/25/19
16:33
Periodicals
Nestle, Novartis among multinationals at risk of London trading ban, WSJ says »

Trading in…

NSRGY

Nestle

$0.00

(0.00%)

NVS

Novartis

$92.37

-0.41 (-0.44%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Sep

DRRX

Durect

$0.67

0.0422 (6.72%)

16:31
06/25/19
06/25
16:31
06/25/19
16:31
Hot Stocks
Durect receives approval to transfer to Nasdaq Capital Market »

Durect Corporation…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.